HBT1

• Description:

  HBT1 is an effective AMPA receptor AMPA-R potentiator. HBT1 specifically binds to the ligand-binding domain (LBD) of AMPAR and enhances receptor activity only when AMPA is present., HBT1 has almost no agonistic effect (i.e., reaching the optimal concentration, and then the efficacy decreases as the concentration continues to increase) compared with traditional AMPA-R potentiator, avoiding the bell-shaped reaction of brain-derived neurotrophic factor (BDNF) production in primary neurons. HBT1 can be applicable to a wider range of neurological and psychiatric diseases (such as depression, Alzheimer's disease, etc.) [1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  IGluR

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel; Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/hbt1.html

• Purity:

  99.73

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(NC1=C(C(N)=O)C(CCCC2)=C2S1)CN3N=C(C(F)(F)F)C=C3C

• Molecular Formula:

  C16H17F3N4O2S

• Molecular Weight:

  386.39

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Akiyoshi Kunugi, et al. HBT1, a Novel AMPA Receptor Potentiator with Lower Agonistic Effect, Avoided Bell-Shaped Response in In Vitro BDNF Production. J Pharmacol Exp Ther. 2018 Mar;364 (3) :377-389.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  AMPA Receptor

• CAS Number:

  489408-02-8